Insider Selling: ABIOMED, Inc. (ABMD) VP Sells $1,786,400.00 in Stock

ABIOMED, Inc. (NASDAQ:ABMD) VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $178.64, for a total value of $1,786,400.00. Following the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

ABIOMED, Inc. (NASDAQ:ABMD) opened at $194.90 on Friday. The stock has a market capitalization of $8.40 billion, a PE ratio of 121.83, a PEG ratio of 2.53 and a beta of 0.23. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02.

ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.16. The business had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The business’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same period last year, the firm posted $0.20 earnings per share. analysts anticipate that ABIOMED, Inc. will post 2.38 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: ABIOMED, Inc. (ABMD) VP Sells $1,786,400.00 in Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/04/insider-selling-abiomed-inc-abmd-vp-sells-1786400-00-in-stock.html.

A number of large investors have recently made changes to their positions in ABMD. Teachers Advisors LLC boosted its position in ABIOMED by 2.7% in the first quarter. Teachers Advisors LLC now owns 43,588 shares of the medical equipment provider’s stock worth $5,457,000 after purchasing an additional 1,136 shares during the last quarter. Legal & General Group Plc boosted its position in ABIOMED by 123.0% in the first quarter. Legal & General Group Plc now owns 25,379 shares of the medical equipment provider’s stock worth $3,177,000 after purchasing an additional 13,999 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in ABIOMED by 4.6% in the first quarter. Dimensional Fund Advisors LP now owns 138,140 shares of the medical equipment provider’s stock worth $17,295,000 after purchasing an additional 6,134 shares during the last quarter. KCG Holdings Inc. boosted its position in ABIOMED by 37.3% in the first quarter. KCG Holdings Inc. now owns 4,845 shares of the medical equipment provider’s stock worth $607,000 after purchasing an additional 1,316 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of ABIOMED by 6.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 113,284 shares of the medical equipment provider’s stock valued at $14,184,000 after buying an additional 7,006 shares in the last quarter. 90.55% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on ABMD. Jefferies Group LLC raised their price target on ABIOMED from $175.00 to $208.00 and gave the company a “buy” rating in a report on Friday, September 29th. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price target on shares of ABIOMED in a report on Tuesday, August 29th. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “strong-buy” rating and set a $163.00 price target for the company in a report on Thursday, July 13th. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Finally, BTIG Research restated a “hold” rating on shares of ABIOMED in a report on Sunday, October 29th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $183.25.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

What are top analysts saying about ABIOMED Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ABIOMED Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit